for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Indivior PLC

INDV.L

Latest Trade

39.00GBp

Change

1.50(+4.00%)

Volume

2,170,711

Today's Range

36.75

 - 

39.18

52 Week Range

20.98

 - 

131.04

As of on the London Stock Exchange (LON) ∙ Minimum 15 minute delay

Latest Developments

Indivior Appoints Graham Hetherington As A Member Of Remuneration Committee

Oct 31 (Reuters) - Indivior PLC <INDV.L>::BOARD COMMITTEE CHANGES.GRAHAM HETHERINGTON WILL BE APPOINTED A MEMBER OF REMUNERATION COMMITTEE WITH EFFECT FROM NOVEMBER 1, 2019..GRAHAM HETHERINGTON WILL BE APPOINTED A MEMBER OF REMUNERATION COMMITTEE WITH EFFECT FROM NOVEMBER 1, 2019..

Indivior Qtrly Net Rev $199 Mln Vs $245 Mln

Oct 31 (Reuters) - Indivior PLC <INDV.L>::INDIVIOR PLC - 3RD QUARTER RESULTS.INDIVIOR PLC - SUBOXONE FILM MARKET SHARE YTD AVERAGED 34% (YTD 2018: 54%) AND EXITED Q3 2019 AT 26% (Q3 2018: 52%).INDIVIOR PLC - FY 2019 NET REVENUE IS EXPECTED TO BE IN RANGE OF $750M TO $790M (PREVIOUSLY: $670M TO $720M).INDIVIOR PLC - QTRLY NET REVENUE $199 MILLION VERSUS $245 MILLION.INDIVIOR PLC - SEES FY NET INCOME IN RANGE OF $160M TO $190M (PREVIOUSLY: $80M TO $130M).INDIVIOR PLC - QTRLY NET INCOME $48 MILLION VERSUS $89 MILLION.INDIVIOR PLC - FY 2019 SUBLOCADE NET REVENUE RANGE NARROWED TO $60M TO $70M (FROM $50M TO $70M).INDIVIOR PLC - QTRLY ADJUSTED. NET INCOME $48 MILLION VERSUS $58 MILLION.INDIVIOR - DESPITE PRESSURE FROM BUPRENORPHINE/NALOXONE FILM GENERICS, SUBOXONE FILM SHARE REMAINED ABOVE OBSERVED ANALOGUES AND EXCEEDED CO'S PLANS.INDIVIOR PLC SAYS "WE REMAIN ACUTELY AWARE OF CHALLENGES IN MARKETPLACE AND LEGAL UNCERTAINTIES".INDIVIOR - 2019 REVENUE GUIDANCE INCLUDES ADVERSE NET REVENUE IMPACT FROM RECENT LEGISLATION CHANGE.INDIVIOR PLC - ENDING YTD 2019 CASH BALANCE WAS $1,023M (FYE 2018: $924M).INDIVIOR -EVEN IF SETTLEMENT CANNOT BE REACHED, OUTCOME FROM DOJ INDICTMENT NOT EXPECTED TO IMPACT CO DURING GOING CONCERN PERIOD OVER NEXT 12 MONTHS.

Reckitt Benckiser Sees 2019 LFL Net Rev Growth Of 0-2%

Oct 22 (Reuters) - Reckitt Benckiser Group PLC <RB.L>::RECKITT BENCKISER GP - Q3 2019 TRADING UPDATE.RECKITT BENCKISER GROUP PLC - FULL YEAR 2019 NET REVENUE GROWTH TARGET REDUCED TO 0-2%.RECKITT BENCKISER GROUP PLC - FULL YEAR 2019 ADJUSTED OPERATING MARGINS EXPECTED TO SEE A MODEST DECLINE.RECKITT BENCKISER GROUP PLC - LFL REVENUE GROWTH IN Q3 OF +1.6%.RECKITT BENCKISER - LOWERED REVENUE OUTLOOK FOR FY 2019 TO REFLECT COMBINATION OF A WEAK HEALTH PERFORMANCE IN Q3 AND INHERENT SEASONAL UNCERTAINTY IN Q4.RECKITT BENCKISER GROUP PLC - RB'S PERFORMANCE IN Q3 WAS DISAPPOINTING.RECKITT BENCKISER - LOWERED REVENUE OUTLOOK FOR FY TO REFLECT COMBINATION OF A WEAK HEALTH PERFORMANCE IN Q3 AND INHERENT SEASONAL UNCERTAINTY IN Q4.RECKITT BENCKISER GROUP PLC - IN CHINA, IFCN CONTINUES TO FACE CHALLENGING MARKET CONDITIONS.RECKITT BENCKISER GROUP PLC - LFL PERFORMANCE IN HEALTH IN Q3 WAS -0.3%, AFTER LAPPING SUPPLY DISRUPTION IN IFCN BUSINESS IN PRIOR YEAR.RECKITT BENCKISER GROUP PLC - HEALTH BUSINESS DELIVERED A WEAK NET REVENUE PERFORMANCE IN QUARTER PRIMARILY DUE TO ISSUES IN US AND CHINA.RECKITT BENCKISER GROUP - IFCN SEGMENT DELIVERED LFL GROWTH OF +7.2% IN QUARTER.RECKITT BENCKISER GROUP Q3 REVENUE ROSE 5.3% ON A REPORTED BASIS TO 3.29 BILLION STG .RECKITT BENCKISER GROUP PLC SEES 2019 LFL NET REVENUE GROWTH OF 0-2% (PREVIOUSLY 2-3%).RECKITT BENCKISER GROUP PLC SEES MODEST ADJUSTED OPERATING MARGIN DECLINE IN 2019 (PREVIOUSLY FLAT).

Indivior Appoints Graham Hetherington As Independent Non-Executive Director

Oct 16 (Reuters) - Indivior PLC <INDV.L>::DIRECTORATE CHANGE.APPOINTMENT OF GRAHAM HETHERINGTON AS AN INDEPENDENT NON-EXECUTIVE DIRECTOR OF COMPANY.HETHERINGTON WILL ALSO BE APPOINTED AS MEMBER OF AUDIT COMMITTEE WITH EFFECT FROM NOV 1, 2019.

Indivior Raises FY Rev, Profit View

Oct 15 (Reuters) - Indivior PLC <INDV.L>::INDIVIOR RAISES FY 2019 GUIDANCE.REVISED EXPECTATIONS FOR FY 2019 NET REVENUE AND NET INCOME FOLLOWING STRONGER-THAN-EXPECTED NET REVENUE PERFORMANCE.CASH AT Q3 2019 EXPECTED TO BE APPROXIMATELY $1,020 MILLION.FY 2019 GROUP NET REVENUE IS NOW EXPECTED TO BE IN RANGE OF $750M TO $790M.SEES FY NET INCOME IN RANGE OF $160M TO $190M.NARROWING FY 2019 NET REVENUE GUIDANCE RANGE FOR SUBLOCADE (BUPRENORPHINE EXTENDED-RELEASE) INJECTION TO $60M TO $70M (FROM $50M TO $70M).REVISED FY 2019 NET REVENUE GUIDANCE ALSO INCLUDES AN EXPECTED ADVERSE NET REVENUE IMPACT FROM RECENT PASSAGE OF H.R. 4378.PRIMARY DRIVER FOR REVISED OUTLOOK IS EXPECTED CONTINUED MARKET SHARE PERFORMANCE THROUGH 2019 OF BRANDED SUBOXONE FILM.GIVEN NOTICE TO SANDOZ INC. OF ITS INTENTION TO CEASE PRODUCTION OF ITS AUTHORIZED GENERIC BUPRENORPHINE/NALOXONE SUBLINGUAL FILM.DOES NOT EXPECT NOTICE TO SANDOZ TO AFFECT PATIENT CHOICE OF BRANDED OR GENERIC BUPRENORPHINE/NALOXONE SUBLINGUAL FILM.NOTICE TO SANDOZ WILL PROTECT GROUP'S ABILITY TO INVEST IN GROWING SUBLOCADE.

Entities Affiliated With Standard Life Aberdeen Disclose 15.83% Stake In Indivior As Of Sept 30 - Filing

Oct 3 (Reuters) - Indivior PLC <INDV.L>::ENTITIES AFFILIATED WITH STANDARD LIFE ABERDEEN DISCLOSE 15.83% STAKE IN INDIVIOR AS OF SEPT 30 VERSUS PRIOR STAKE OF 18.92% - FILING.

Indivior PLC Says Howard Pien Bought 50,000 Shares At $0.7359 Per Share On Aug 8

Aug 9 (Reuters) - Indivior PLC <INDV.L>::HOWARD PIEN, CHAIR, BOUGHT 50,000 SHARES AT $0.746725 PER SHARE ON AUG 7; ACQUIRED 50,000 SHARES AT $0.7359 PER SHARE ON AUG 8.

Indivior CEO Says Preparing For Trial On U.S. DoJ Indictment Into Marketing Of Suboxone

July 31 (Reuters) - Indivior CEO Shaun Thaxter (Conference Call)::ON U.S. DOJ INVESTIGATION INTO MARKETING OF SUBOXONE, SAYS PREPARING FOR TRIAL, BUT NOT ALLOWED TO DISCLOSE ANYTHING FURTHER.UNAWARE WHY SUBOXONE MARKET SHARE EROSION IS SLOWER THAN EXPECTED, DO NOT SEE THIS MARKET SHARE RETENTION SUSTAINING .DO NO EXPECT SUBLOCADE SALES TO SLOW DOWN IN SECOND HALF OF THE YEAR - CONF CALL .

Indivior Says Q2 Pretax Profit Rises 14%

July 31 (Reuters) - Indivior PLC <INDV.L>::HALF-YEAR REPORT.HY NET REVENUE OF $454M DECLINED 13%.HY REPORTED OPERATING PROFIT WAS $163M (H1 2018: $200M).FY 2019 NET REVENUE IS EXPECTED TO BE IN RANGE OF $670M TO $720M (PREVIOUSLY: $525M TO $575M).HY NET REVENUE DECLINED 12% PRIMARILY DUE TO SUBOXONE FILM SHARE LOSS TO GENERIC COMPETITORS.SUBOXONE FILM MARKET SHARE DURING H1 2019 AVERAGED 38% (H1 2018: 54%) AND EXITED AT 27% (H1 2018: 52%).SEES FY 2019 NET INCOME IN RANGE OF $80M TO $130M (PREVIOUSLY: A LOSS OF $40M TO NET INCOME OF $10M).ENDING H1 2019 CASH BALANCE WAS $988M (FY 2018: $924M).SEES FY 19 SUBLOCADE NET REVENUE OF $50M TO $70M.SEES MODEST NET REVENUE CONTRIBUTION FROM PERSERIS IN FY 19.NOT POSSIBLE TO PREDICT WITH ANY CERTAINTY POTENTIAL IMPACT OF DOJ LITIGATION.NOT POSSIBLE TO QUANTIFY ULTIMATE COST OF VERDICT OR RESOLUTION ON DOJ MATTER, BUT IT COULD HAVE A MATERIAL IMPACT ON GROUP.

Indivior Names CFO Mark Crossley As Chief Financial & Operations Officer

July 29 (Reuters) - Indivior Plc<INDV.L>::DIRECTOR'S CHANGE OF RESPONSIBILITIES.FRANK STIER, CHIEF MANUFACTURING AND SUPPLY OFFICER, HAS INFORMED COMPANY THAT HE PLANS TO RETIRE IN 2020.MARK CROSSLEY, CURRENTLY CHIEF FINANCIAL OFFICER, IS APPOINTED CHIEF FINANCIAL AND OPERATIONS OFFICER.FRANK WILL NOW REPORT DIRECTLY TO MARK (AS WILL FRANK'S SUCCESSOR ONCE APPOINTED).

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up